Oxford Biomedica has agreed to a three-year extension of its lentiviral vector agreement for several of Novartis’ CAR-T products. Oxford Biomedica originally licensed its LentiVector platform to Swiss drugmaker Novartis in October 2014 and later both parties inked a five year vector supply extension in December 2019. Under the terms of the latest deal, both firms have extended the commercial supply agreement until the end of 2028 and Oxford Biomedica has regained the rights to its LentiVector platform and has…
